Herrschaft, Horst, Nacu, Anatol, Likhachev, Sergey, Sholomov, Ilya, Hoerr, Robert, Schlaefke, Sandra

A multi-centre, double-blind, randomised, placebo-controlled, 24-week trial with 410 outpatients was conducted to demonstrate efficacy and safety of a 240 mg once-daily formulation of Ginkgo biloba extract EGb 761(®) in patients with mild to moderate dementia (Alzheimer’s disease or vascular dementia) associated with neuropsychiatric symptoms. Patients scored 9 to 23 on the SKT cognitive battery, […]

Green, Robert C., Schneider, Lon S., Amato, David A., Beelen, Andrew P., Wilcock, Gordon, Swabb, Edward A., Zavitz, Kenton H.

Context: Amyloid-beta peptide (Abeta(42)) has been implicated in the pathogenesis of Alzheimer disease (AD). Tarenflurbil, a selective Abeta(42)-lowering agent, demonstrated encouraging results on cognitive and functional outcomes among mildly affected patients in an earlier phase 2 trial.; Objective: To determine the efficacy, safety, and tolerability of tarenflurbil.; Design, Setting, and Patients: A multicenter, randomized, double-blind, […]

Beglinger, Leigh J., Adams, Williams H., Paulson, Henry, Fiedorowicz, Jess G., Langbehn, Douglas R., Duff, Kevin, Leserman, Anne, Paulsen, Jane S.

Background: Cognitive symptoms are associated with functional disability in Huntington disease; yet, few controlled trials have examined cognitive treatments that could improve patient independence and quality of life. Atomoxetine is a norepinephrine reuptake inhibitor approved for treatment of attention-deficit/hyperactivity disorder.; Methods: Twenty participants with mild Huntington disease who complained of inattention were randomized to receive […]